News
AbbVie's $10.9 Billion Bet on Apogee: What Big Pharma's Biggest Deal of the Summer Reveals About the Post-Humira Era
AbbVie's $10.9 billion acquisition of Apogee Therapeutics signals a major shift in Big Pharma strategy. The deal reveals where pharmaceutical giants believe the next decade of drug revenue is coming from—and why they're willing to pay premium prices for late-stage biotech assets.